NIET TOEGEWEZEN Het gedrag van personen met diabetes (bijv. behandeling) en het gedrag van artsen en verschillende beroepsbeoefenaren in de gezondheidszorg (bijv. controle van de bloedsuikerspiegel van patiënten) zijn essentieel.
Onze onderzoeksgroep moest één gedrag van betrokkenen en één gedrag van bekwame zorgverleners kiezen als proefpersonen in Ierland. Patiënten en beroepsbeoefenaren in de gezondheidszorg worden meestal niet vaak gevraagd om te helpen bij het oplossen van onderzoeksonderwerpen.
In dit onderzoek moesten we collectief patiënten, zorgverleners en dekkingsmakers overbrengen om ons te helpen bij het oplossen van het meest essentiële doelgedrag voor onderzoek naar diabetes in Ierland. We werkten met 24 medewerkers, samen met mensen met diabetes, diabetesprofessionals en dekkingsmakers.
Ten eerste gaven de bijdragers instructies over gedragingen waarvan zij dachten dat ze essentieel waren voor onderzoek naar diabetes. Deelnemers woonden vervolgens een bijeenkomst bij en beoordeelden welk van de gedragingen het meest essentieel waren en noemden de resultaten van de ranglijst als een groep. We herkenden het meest extreem gerangschikte gedrag van getroffen personen en zorgverleners.
Het belangrijkste gerangschikte gedrag voor mensen met diabetes type 1 was ‘insuline nemen zoals vereist’ en voor mensen met diabetes type 2 was ‘het bijwonen van en interactie hebben met gestructureerde scholingsprogramma’s’. ‘Betrokkenheid bij het stellen van samenwerkingsdoelen met patiënten’ was het belangrijkste gedrag van zorgprofessionals.
Uit ons onderzoek blijkt dat het voor onderzoekers goed te doen is om samen te werken met mensen met diabetes, beroepsbeoefenaren in de gezondheidszorg en makers van dekkingen om onderzoeksonderwerpen op te lossen. De eerst gerangschikte gedragingen zullen nu worden onderzocht door onze groep in Ierland. UNASSIGNED Achtergrond Werken met patiënten, zorgverleners en dekkingsmakers om prioriteit te geven aan onderzoek onderwerpen kunnen de relevantie van onderzoek verbeteren en de kans vergroten dat onderzoeksresultaten worden omgezet in waarneming.
Het doel van het huidige onderzoek was om samen te werken met de belangrijkste belanghebbenden om te bepalen en consensus te bereiken over het meest essentiële doelgedrag voor onderzoek naar diabetes in Ierland. Methoden Vierentwintig bijdragers, samen met mensen met diabetes, diabetesprofessionals en dekkingsmakers, namen de helft in een nominale consensuscursus voor groepstechnieken.
Via een webgebaseerde enquête genereerden de bijdragers lijsten van essentieel doelgedrag op drie gebieden: diabetes type 1 beheren, diabetes type 2 beheren en diabetes type 2 stoppen.
Prioritising target behaviours for research in diabetes: Using the nominal group technique to achieve consensus from key stakeholders.
Deelnemers woonden vervolgens een onderzoeksprioriteringsassemblage bij en rangschikten doelgedrag in twee rondes, met een groepsdialoog tussen beoordelingsrondes. Voor elk van de drie belangrijkste gebieden hadden de zes eerst gerangschikte gedragingen betrekking op mensen met diabetes en beroepsbeoefenaren in de gezondheidszorg zijn erkend.
Resultaten In de meeste gevallen was het meest extreem gerangschikte gedrag vergelijkbaar voor rangorde 1 en rangschikking 2 en was er een grotere consensus met betrekking tot het onderschrijven van eersteklas gedrag. Sommige gedragingen veranderden echter van plaats tussen ranglijsten.
Growth Blocking Peptide - I-125 Labeled
T-046-92
PHOENIX PEPTIDE
10 μCi
EUR 1145.88
40787 Blocking Peptide
33R-2900
Fitzgerald
100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SEPT1 antibody, catalog no. 70R-9926
hCG_1982709 Blocking Peptide
33R-3437
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_1982709 antibody, catalog no. 70R-9054
hCG_2042202 Blocking Peptide
33R-3770
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_2042202 antibody, catalog no. 70R-9063
hCG_1660138 Blocking Peptide
33R-4078
Fitzgerald
100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_1660138 antibody, catalog no. 70R-9044
hCG_1646157 Blocking Peptide
33R-4162
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_1646157 antibody, catalog no. 70R-9034
hCG_20426 Blocking Peptide
33R-4753
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_20426 antibody, catalog no. 70R-8776
hCG_2007354 Blocking Peptide
33R-5366
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_2007354 antibody, catalog no. 70R-9061
hCG_20426 Blocking Peptide
33R-5875
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_20426 antibody, catalog no. 70R-8775
HCG_1745121 Blocking Peptide
33R-6558
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_1745121 antibody, catalog no. 70R-3903
hCG_1646157 Blocking Peptide
33R-7420
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hCG_1646157 antibody, catalog no. 70R-9035
F7 Blocking Peptide
33R-1026
Fitzgerald
100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DLG4 antibody, catalog no. 70R-4080
GC Blocking Peptide
33R-10350
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GC antibody, catalog no. 70R-10252
A1 Blocking Peptide
33R-10744
Fitzgerald
50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of A1 antibody, catalog no. 70R-11802
KC Blocking Peptide
33R-11041
Fitzgerald
50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KC antibody, catalog no. 70R-12298
F2 Blocking Peptide
33R-1783
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of F2 antibody, catalog no. 70R-8514
PB Blocking Peptide
33R-2067
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of pb antibody, catalog no. 70R-2192
AC Blocking Peptide
33R-3003
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ac antibody, catalog no. 70R-1978
TH Blocking Peptide
33R-3167
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TH antibody, catalog no. 70R-7854
F8 Blocking Peptide
33R-3569
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of F8 antibody, catalog no. 70R-9971
NP Blocking Peptide
33R-3631
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NP antibody, catalog no. 70R-2286
GC Blocking Peptide
33R-4418
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GC antibody, catalog no. 70R-10253
XK Blocking Peptide
33R-5017
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of XK antibody, catalog no. 70R-7169
SI Blocking Peptide
33R-5258
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SI antibody, catalog no. 70R-7230
GK Blocking Peptide
33R-5595
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GK antibody, catalog no. 70R-4533
TH Blocking Peptide
33R-6309
Fitzgerald
100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TH antibody, catalog no. 70R-10442
HB Blocking Peptide
33R-6336
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of hb antibody, catalog no. 70R-3198
N Blocking Peptide
33R-6561
Fitzgerald
100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of LSM8 antibody, catalog no. 70R-4590
SI Blocking Peptide
33R-6891
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SI antibody, catalog no. 70R-7205
XK Blocking Peptide
33R-7655
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of XK antibody, catalog no. 70R-7274
F7 Blocking Peptide
33R-7835
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of F7 antibody, catalog no. 70R-9970
PC Blocking Peptide
33R-8614
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PC antibody, catalog no. 70R-9828
A1 Blocking Peptide
3401BP-50
Biovision
each
EUR 183.6
C6 Blocking Peptide
DF3963-BP
Affbiotech
1mg
EUR 234
C9 Blocking Peptide
DF3964-BP
Affbiotech
1mg
EUR 234
MB Blocking Peptide
DF4194-BP
Affbiotech
1mg
EUR 234
NT Blocking Peptide
DF4245-BP
Affbiotech
1mg
EUR 234
PC Blocking Peptide
DF4364-BP
Affbiotech
1mg
EUR 234
AR Blocking Peptide
DF6783-BP
Affbiotech
1mg
EUR 234
MB Blocking Peptide
DF7358-BP
Affbiotech
1mg
EUR 234
FH Blocking Peptide
DF7460-BP
Affbiotech
1mg
EUR 234
F3 Blocking Peptide
DF6400-BP
Affbiotech
1mg
EUR 234
HP Blocking Peptide
DF6467-BP
Affbiotech
1mg
EUR 234
F9 Blocking Peptide
DF6474-BP
Affbiotech
1mg
EUR 234
GK Blocking Peptide
DF3151-BP
Affbiotech
1mg
EUR 234
C5 Blocking Peptide
DF7719-BP
Affbiotech
1mg
EUR 234
GC Blocking Peptide
DF7840-BP
Affbiotech
1mg
EUR 234
TG Blocking Peptide
DF7885-BP
Affbiotech
1mg
EUR 234
F5 Blocking Peptide
DF8265-BP
Affbiotech
1mg
EUR 234
Ob Blocking Peptide
DF8583-BP
Affbiotech
1mg
EUR 234
ST Blocking Peptide
DF8616-BP
Affbiotech
1mg
EUR 234
CP Blocking Peptide
DF9369-BP
Affbiotech
1mg
EUR 234
C7 Blocking Peptide
DF9410-BP
Affbiotech
1mg
EUR 234
OR Blocking Peptide
DF10250-BP
Affbiotech
1mg
EUR 234
GK Blocking Peptide
AF0829-BP
Affbiotech
1mg
EUR 234
GR Blocking Peptide
AF6066-BP
Affbiotech
1mg
EUR 234
GR Blocking Peptide
AF6067-BP
Affbiotech
1mg
EUR 234
TK Blocking Peptide
AF6068-BP
Affbiotech
1mg
EUR 234
IR Blocking Peptide
AF6098-BP
Affbiotech
1mg
EUR 234
IR Blocking Peptide
AF6099-BP
Affbiotech
1mg
EUR 234
GR Blocking Peptide
AF5004-BP
Affbiotech
1mg
EUR 234
KC Blocking Peptide
5212BP-50
Biovision
each
EUR 183.6
T Blocking Peptide
BF0015-BP
Affbiotech
1mg
EUR 234
AR Blocking Peptide
BF0418-BP
Affbiotech
1mg
EUR 234
PR Blocking Peptide
BF0581-BP
Affbiotech
1mg
EUR 234
RB Blocking Peptide
BF0614-BP
Affbiotech
1mg
EUR 234
ER Blocking Peptide
BF0674-BP
Affbiotech
1mg
EUR 234
E7 Blocking Peptide
BF0311-BP
Affbiotech
1mg
EUR 234
TK Blocking Peptide
AF7678-BP
Affbiotech
1mg
EUR 234
Rb Blocking Peptide
AF7698-BP
Affbiotech
1mg
EUR 234
Ub Blocking Peptide
20-abx063395
Abbexa
Ask for price
Ask for price
FX Blocking Peptide
20-abx161511
Abbexa
Ask for price
Ask for price
GW Blocking Peptide
20-abx162574
Abbexa
Ask for price
Ask for price
PEPT1 Blocking Peptide
20-abx063272
Abbexa
Ask for price
Ask for price
Bax Blocking Peptide
3032BP-50
Biovision
each
EUR 183.6
p53 Blocking Peptide
3036RBP-50
Biovision
each
EUR 183.6
PBR Blocking Peptide
3044BP-50
Biovision
each
EUR 183.6
Akt Blocking Peptide
3247BP-50
Biovision
each
EUR 183.6
Bid Blocking Peptide
3272BP-50
Biovision
each
EUR 183.6
RIP Blocking Peptide
3279BP-50
Biovision
each
EUR 183.6
AT2 Blocking Peptide
30R-AA024
Fitzgerald
100 ug
EUR 195
Description: A synthetic AT2 Blocking peptide for use as a blocking control in assays to test for specificity of AT2 antibody, catalog no. 70R-AR006
NIK Blocking Peptide
3193RBP-50
Biovision
each
EUR 183.6
AIF Blocking Peptide
3202BP-50
Biovision
each
EUR 183.6
DR6 Blocking Peptide
3216RBP-50
Biovision
each
EUR 183.6
DR4 Blocking Peptide
3061BP-50
Biovision
each
EUR 183.6
DR5 Blocking Peptide
3062BP-50
Biovision
each
EUR 183.6
PKA Blocking Peptide
3115BP-50
Biovision
each
EUR 183.6
Bid Blocking Peptide
3172BP-50
Biovision
each
EUR 183.6
BMF Blocking Peptide
3334RBP-50
Biovision
each
EUR 183.6
OMP Blocking Peptide
33R-10003
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of OMP antibody, catalog no. 70R-2611
FTO Blocking Peptide
33R-10037
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FTO antibody, catalog no. 70R-4523
F2R Blocking Peptide
33R-10057
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of F2R antibody, catalog no. 70R-9967
MYB Blocking Peptide
33R-10068
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MYB antibody, catalog no. 70R-8269
UST Blocking Peptide
33R-10095
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of UST antibody, catalog no. 70R-1825
SDS Blocking Peptide
33R-1011
Fitzgerald
100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DISC1 antibody, catalog no. 70R-2399
Gns Blocking Peptide
33R-10135
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Gns antibody, catalog no. 70R-8622
CNP Blocking Peptide
33R-10149
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CNP antibody, catalog no. 70R-1054
Utx Blocking Peptide
33R-10306
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Utx antibody, catalog no. 70R-7989
GBA Blocking Peptide
33R-10317
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GBA antibody, catalog no. 70R-10294
AK7 Blocking Peptide
33R-10319
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of AK7 antibody, catalog no. 70R-10381
Mkx Blocking Peptide
33R-10329
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Mkx antibody, catalog no. 70R-8448
Zfr Blocking Peptide
33R-10340
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Zfr antibody, catalog no. 70R-8321
CCS Blocking Peptide
33R-10355
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CCS antibody, catalog no. 70R-10221
IDE Blocking Peptide
33R-10357
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of IDE antibody, catalog no. 70R-7840
CAD Blocking Peptide
33R-1037
Fitzgerald
100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RNASEN antibody, catalog no. 70R-4643
GP9 Blocking Peptide
33R-10371
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GP9 antibody, catalog no. 70R-10332
Tat Blocking Peptide
33R-10377
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Tat antibody, catalog no. 70R-8790
GCK Blocking Peptide
33R-10396
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GCK antibody, catalog no. 70R-10324
AGA Blocking Peptide
33R-10401
Fitzgerald
100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of AGA antibody, catalog no. 70R-10228
Bax Blocking Peptide
33R-10443
Fitzgerald
50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bax antibody, catalog no. 20R-1435
p53 Blocking Peptide
33R-10444
Fitzgerald
50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of p53 antibody, catalog no. 20R-1436
PKA Blocking Peptide
33R-10449
Fitzgerald
50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PKA antibody, catalog no. 20R-1459
Bid Blocking Peptide
33R-10457
Fitzgerald
50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bid antibody, catalog no. 20R-1486
Akt Blocking Peptide
33R-10462
Fitzgerald
50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Akt antibody, catalog no. 20R-1501
ALK Blocking Peptide
33R-10471
Fitzgerald
50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ALK antibody, catalog no. 20R-1521
AFX Blocking Peptide
33R-10484
Fitzgerald
50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of AFX antibody, catalog no. 20R-1555
PKC Blocking Peptide
33R-10494
Fitzgerald
50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PKC antibody, catalog no. 20R-1581
Lck Blocking Peptide
33R-10503
Fitzgerald
50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Lck antibody, catalog no. 20R-1612
FAH Blocking Peptide
33R-1054
Fitzgerald
100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of EPN1 antibody, catalog no. 70R-3618
JNK Blocking Peptide
33R-10543
Fitzgerald
50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of JNK antibody, catalog no. 20R-1708
Brk Blocking Peptide
33R-10558
Fitzgerald
50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Brk antibody, catalog no. 20R-1742
DUT Blocking Peptide
33R-1060
Fitzgerald
100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of UGCGL1 antibody, catalog no. 70R-4490
Bax Blocking Peptide
33R-10601
Fitzgerald
50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bax antibody, catalog no. 70R-11570
p53 Blocking Peptide
33R-10604
Fitzgerald
50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of p53 antibody, catalog no. 70R-11573
PBR Blocking Peptide
33R-10608
Fitzgerald
50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PBR antibody, catalog no. 70R-11578
DR4 Blocking Peptide
33R-10613
Fitzgerald
50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DR4 antibody, catalog no. 70R-11590
DR5 Blocking Peptide
33R-10614
Fitzgerald
50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DR5 antibody, catalog no. 70R-11591
Rac Blocking Peptide
33R-10620
Fitzgerald
50 ug
EUR 145
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Rac antibody, catalog no. 70R-11597
Het belangrijkste gedrag gerelateerd aan mensen met diabetes type 1 was ‘insuline nemen zoals vereist’ en voor mensen met diabetes type 2 was ‘het bijwonen en fascineren met gestructureerde scholingsprogramma’s’. ‘Betrokkenheid bij het stellen van samenwerkingsdoelen met patiënten’ was het belangrijkste gerangschikte gedrag met betrekking tot beroepsbeoefenaren in de gezondheidszorg voor het beheren van elke type 1- en type 2-diabetes. Voor het stoppen van diabetes type 2 was ‘interactie hebben met gezond gedrag als huishouden’ het hoogst gerangschikte gedrag van de bewoners en ‘wonen en interactie hebben met coaching voor gedragsverandering’ was het hoogst bekwame gedrag.
Conclusies Het is mogelijk om samen te werken met een verschillende groep belanghebbenden om de onderzoeksagenda voor diabetes te informeren. De erkende prioriteiten zijn mede tot stand gekomen door de belangrijkste belanghebbenden, samen met patiënten, zorgverleners en dekkingsmakers, en kan de groei van een programma voor gedragsonderzoek bij diabetes in Ierland informeren.
Het onderzoek biedt bovendien een moeizaam voorbeeld van een cursus onderzoeksprioritering met gebruikmaking van de nominale groepstechniek en erkende beperkingen, die nuttig kunnen zijn voor verschillende onderzoekers.